

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-367

C#/M#

MOSER et al

Group Art Unit:

Serial No. 09/314,159

Examiner:

Filed: May 19, 1999

Date: October 20, 1999

Title: ANGIOSTATIN RECEPTOR

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 78.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$ 110.00 /1 month; \$380.00/2 months; \$870.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$110.00 \$ 0.00

First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$760.00) \$ 0.00

Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$760.00) \$ 0.00

☐ Please enter the previously unentered filed

**SUBTOTAL \$ 0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee ( \$40.00 ) \$ 0.00

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road  
8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat

**NIXON & VANDERHVE P.C.**

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-367

C#/M#

Group Art Unit:

Examiner:

Date: October 20, 1999

MOSER et al

Serial No. 09/314,159

Filed: May 19, 1999

Title: ANGIOSTATIN RECEPTOR

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 78.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$ 110.00 /1 month; \$380.00/2 months; \$870.00/3 months)				\$ 0.00
Terminal disclaimer enclosed, add \$110.00				\$ 0.00
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$760.00)				\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$760.00)				\$ 0.00

☐ Please enter the previously unentered filed**SUBTOTAL** \$ 0.00If "small entity," then enter half (1/2) of subtotal and subtract  
☐ Statement filed herewith - \$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee ( \$40.00 ) \$ 0.00

**TOTAL FEE ENCLOSED** \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road  
8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat**NIXON & VANDERHYE P.C.**

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

MOSER et al

Atty. Ref.: 1579-367

Serial No.: 09/314,159

Group Art Unit:

Filed: May 19, 1999

Examiner:

For: **ANGIOSTATIN RECEPTOR**

\* \* \* \* \*

October 20, 1999

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Attached is Form PTO-1449 listing the enclosed documents, together with an International Search Report, dated October 14, 1999, issued in a counterpart PCT application.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 14-1140 (1579-367) and proceed to consider this IDS.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.